How Your Body Converts Psilocybin to Psilocin

Psilocybin Fundamentals

Nearly undetectable in blood plasma

In pharmacokinetic studies, parent psilocybin is almost absent in blood plasma after oral ingestion — confirming near-complete conversion to psilocin before entering the bloodstream.

Brown et al., Clinical Pharmacokinetics, 2017

Alkaline phosphatase

the enzyme at 3 simultaneous sites — gut wall, liver, and blood plasma — that performs the conversion (Dinis-Oliveira 2017)

Negatively charged

what the phosphate group does to psilocybin — preventing membrane crossing and receptor binding until removed (Glatfelter 2022)

More stable

why mushrooms store psilocybin rather than psilocin — the phosphate form resists degradation far better (Geiger 2018)

Brown et al., Clinical Pharmacokinetics, 2017

View as image ↗

Every account of psilocybin pharmacology includes some version of: "psilocybin converts to psilocin, which is the active compound." What those accounts almost never explain is the specific enzyme doing the conversion, the three locations where it simultaneously happens, why psilocybin needs a conversion step at all, or what the chemical consequence of the phosphate group's presence actually is.

The conversion is not a slow or uncertain process. In pharmacokinetic studies, the parent psilocybin molecule is almost completely absent in blood plasma shortly after ingestion — it has already been converted.^[2] The reaction is fast and efficient, and the body runs it across three different tissue compartments in parallel. Understanding it explains the onset timing, clarifies why re-dosing too soon is a common mistake, and reveals why mushrooms evolved to store psilocybin rather than psilocin in the first place.

For the broader picture of how psilocybin works as a pharmacological compound, the guide to how psilocybin works covers the full mechanism. For the structural differences between psilocybin and psilocin as molecules, the article on psilocybin vs. psilocin covers the molecular comparison in detail.

The Conversion Step in Plain Terms

Psilocybin is psilocin plus a phosphate group attached to the molecule. That single chemical difference — one phosphate group on the 4-position of the indole ring — is the entire structural distinction between the two compounds. The body converts psilocybin to psilocin by removing that phosphate group through a chemical reaction called dephosphorylation.

Dephosphorylation is a hydrolysis reaction: a water molecule breaks the bond between the phosphate group and the rest of the molecule. The enzyme that catalyzes this reaction is alkaline phosphatase.

That is the conversion step in its entirety: alkaline phosphatase cleaves one phosphate group from psilocybin, producing psilocin. The reaction is fast, enzymatically efficient, and happens across multiple tissue compartments simultaneously.

Three Simultaneous Locations: Where the Conversion Happens

Dinis-Oliveira and colleagues reviewed the full metabolic pathway for psilocybin and psilocin in detail in 2017, establishing where in the body the dephosphorylation occurs.^[1] Alkaline phosphatase is not concentrated in one organ. It is present in multiple tissues throughout the gastrointestinal and hepatic system, and the conversion proceeds in parallel across three locations.

Gut mucosa: The intestinal lining contains alkaline phosphatase in the brush border membrane of enterocytes — the cells lining the small intestine. As psilocybin passes through the intestinal mucosa during absorption, some of it is converted to psilocin at this first site of contact.

Liver (hepatic first-pass): Blood from the intestines passes through the liver via the portal vein before entering systemic circulation. This first-pass effect is a significant site of psilocybin conversion. The liver's alkaline phosphatase activity converts much of the psilocybin that survived intact from the gut.

Blood plasma: Alkaline phosphatase is also active in blood plasma itself. Any psilocybin that reaches systemic circulation is subject to conversion there as well.

The consequence of three simultaneous conversion sites is rapid and nearly complete conversion. The first dose of psilocybin an individual swallows arrives in systemic circulation as psilocin, not as psilocybin.

The Chemical Proof: Why Parent Psilocybin Essentially Vanishes

Brown and colleagues conducted one of the most methodologically rigorous oral psilocybin pharmacokinetic studies in 2017, measuring plasma concentrations of both psilocybin and psilocin across escalating doses.^[2]

The key finding is not the psilocin data. It is the psilocybin data. Parent psilocybin — the original prodrug compound — was barely detectable in blood plasma in most subjects, even at the highest doses tested. This confirmed that conversion is not merely rapid: it is near-complete. By the time the compound reaches systemic circulation, the body has already performed the dephosphorylation reaction.

Brown also confirmed dose-proportional psilocin exposure: higher doses produce proportionally higher psilocin plasma concentrations, confirming that the conversion step does not create a ceiling effect. The body processes more psilocybin into more psilocin in a linear way across the therapeutic dose range. The psilocin half-life measured in this study was approximately 1.8–2 hours.

Why the Phosphate Group Has to Come Off: The Structural Reason

The conversion step is not arbitrary. Psilocybin without conversion cannot produce psychoactive effects for two specific reasons, both connected to the phosphate group.

Reason 1: Membrane crossing. Cell membranes are lipid bilayers that favor uncharged, lipophilic molecules for passive transport. The phosphate group on psilocybin is a polar, negatively charged moiety at physiological pH. This charge makes psilocybin too hydrophilic to cross cell membranes efficiently, including the blood-brain barrier. Psilocin, without the phosphate, is sufficiently uncharged and lipophilic to cross membranes by passive diffusion.

Glatfelter and colleagues confirmed this through structure-activity relationship analysis in 2022, demonstrating that the phosphorylated form of indole alkaloids cannot penetrate membranes to produce CNS effects, while the dephosphorylated forms can.^[4]

Reason 2: Receptor binding. The 5-HT2A serotonin receptor binding pocket is shaped to accept specific molecular geometries. Psilocin fits this pocket and acts as a partial agonist. The phosphate group on psilocybin adds steric bulk and charge that prevents the molecule from fitting the binding site correctly. Psilocybin does not bind 5-HT2A receptors with any meaningful affinity; psilocin does.

This is why psilocybin has no direct psychoactive effects. The intact molecule cannot reach the brain or bind receptors. Only after conversion to psilocin can the compound reach its pharmacological target.

Why Mushrooms Store the Prodrug Instead of the Active Compound

If psilocin is the active compound, why do psilocybin-containing mushrooms store psilocybin rather than psilocin? The answer is stability.

Geiger and colleagues reviewed the chemical properties of psilocybin in detail in 2018, addressing this question directly.^[3] Psilocybin, with its phosphate group, is considerably more chemically stable than psilocin. Psilocin is an indole compound with a free hydroxyl group at the 4-position, which makes it susceptible to oxidation and other degradation reactions under normal storage conditions. Psilocybin's phosphate group masks this hydroxyl, protecting the molecule.

In practical terms: psilocybin remains stable in dried mushrooms stored at room temperature for extended periods. Psilocin, if present as the free compound, would degrade substantially faster under the same conditions.

This stability advantage is also why pharmaceutical-grade psilocybin for clinical trials is synthesized and stored as the phosphate ester. The prodrug form can be weighed and stored precisely; the active form cannot. The body's conversion machinery provides the activation step that pharmaceutical storage conditions would have degraded.

This same stability principle explains why the 4-phosphoryloxy ester is a conserved chemical feature across multiple psilocybin mushroom species. It is an evolutionary solution to the storage problem.

The Practical Implication: Why Onset Takes 30–60 Minutes

The three-site conversion process happens quickly, but it is not instantaneous. Psilocybin must first be absorbed through the gut, converted at the gut mucosa and liver during first-pass, and circulate to the brain where psilocin concentrations build to effective levels.

The combined absorption and conversion process accounts for the 30–60 minute onset window documented in pharmacokinetic studies. At 30 minutes post-ingestion, conversion is actively occurring but psilocin plasma levels have not yet peaked. Peak plasma concentrations are typically reached 1.5–4 hours after ingestion, with the wide range reflecting individual differences in gastric emptying, gut transit, and alkaline phosphatase activity.

The practical consequence is that someone who takes psilocybin and feels nothing at 45 minutes has not failed to absorb the compound. They are likely in the middle of the conversion and absorption process, with rising but sub-peak psilocin levels. Re-dosing at 45 minutes risks a double peak when both doses complete conversion simultaneously. This is one of the most common dosing errors in both research and naturalistic contexts, and the pharmacokinetics of the conversion step explain why it happens. For detailed guidance on timing, the article on psilocybin pharmacokinetics covers the full onset, peak, and duration timeline with plasma concentration data.

What Happens After: Psilocin's Own Metabolism

Once psilocin has been produced and has produced its pharmacological effects, a second and entirely separate metabolic pathway handles its elimination.

Dinis-Oliveira's 2017 review detailed the psilocin metabolism pathway.^[1] Psilocin is primarily metabolized by two routes:

CYP2D6 and CYP3A4 (cytochrome P450 enzymes): These liver enzymes hydroxylate psilocin, producing hydroxylated metabolites. CYP2D6 is particularly important, and genetic polymorphisms in CYP2D6 explain some of the substantial inter-individual variation in psilocin effects. CYP2D6 poor metabolizers may experience stronger and longer effects from the same dose; ultrarapid metabolizers may experience shorter and milder effects.

MAO-A (monoamine oxidase A): This enzyme performs oxidative deamination on psilocin, producing 4-hydroxyindole-3-acetic acid (4-HIAA) and 4-hydroxytryptophol (4-HTOL) as primary metabolites. These metabolites are pharmacologically inactive and are excreted in urine.

The CYP-mediated and MAO-mediated pathways are distinct from the alkaline phosphatase dephosphorylation step. They operate on psilocin after conversion, not on psilocybin directly. This means drugs that inhibit CYP2D6 or MAO-A may extend psilocin's duration of action, while inducers may shorten it. For the complete picture of what happens after psilocin reaches the brain, the article on what happens in your brain on psilocybin covers the receptor binding and neural effects.

The Bottom Line

Psilocybin is converted to psilocin by alkaline phosphatase at three simultaneous sites — the gut mucosa, the liver during first-pass metabolism, and blood plasma. The conversion is near-complete and rapid; pharmacokinetic studies show parent psilocybin is barely detectable in blood plasma after oral ingestion. The conversion is necessary because psilocybin's phosphate group prevents both membrane crossing and receptor binding; removing it creates psilocin, which can cross the blood-brain barrier and bind 5-HT2A receptors. Mushrooms store psilocybin (not psilocin) because the phosphate form is far more chemically stable. After conversion and pharmacological action, psilocin is eliminated via CYP2D6, CYP3A4, and MAO-A — a separate metabolic pathway with its own sources of individual variation.

Frequently Asked Questions

What converts psilocybin to psilocin in the body?

Alkaline phosphatase is the enzyme that converts psilocybin to psilocin. It removes the phosphate group from psilocybin through a hydrolysis reaction called dephosphorylation. Alkaline phosphatase is distinct from the CYP enzymes (CYP2D6, CYP3A4) that metabolize psilocin in a later and separate step. CYP enzymes act after the conversion is complete, not before it.

Where in the body does psilocybin become psilocin?

Conversion happens simultaneously at three locations: the gut mucosa (intestinal lining, during absorption), the liver (during hepatic first-pass metabolism), and blood plasma. Alkaline phosphatase is present in all three compartments. The parallel processing across three sites is what makes the conversion so rapid and near-complete — by the time psilocybin reaches systemic circulation, the majority has already been converted.

Is psilocin or psilocybin the active compound?

Psilocin is the pharmacologically active compound. Psilocybin is inactive — it cannot cross the blood-brain barrier and does not bind serotonin receptors in its intact form. The phosphate group on psilocybin makes the molecule negatively charged and too bulky to enter receptor binding sites. Only after dephosphorylation removes the phosphate group does the resulting psilocin become capable of crossing membranes and binding 5-HT2A receptors.

How fast is psilocybin converted to psilocin?

Conversion begins immediately after oral ingestion and is largely complete by the time psilocybin enters systemic circulation. In pharmacokinetic studies, parent psilocybin is barely detectable in blood plasma, confirming near-complete first-pass conversion. However, the onset of subjective effects takes 30–60 minutes because psilocin must first reach sufficient plasma concentrations and cross the blood-brain barrier. The conversion itself is faster than the absorption and distribution process that follows it.

What enzyme dephosphorylates psilocybin?

Alkaline phosphatase. It is a ubiquitous enzyme present in gut mucosa, liver, and blood plasma. It performs dephosphorylation — a hydrolysis reaction that cleaves the phosphate group from the 4-position of the psilocybin molecule, producing psilocin. Alkaline phosphatase activity varies somewhat between individuals, adding one more source of inter-individual variability in how quickly psilocybin's effects begin.

Why does psilocybin need to be converted to work?

Psilocybin cannot work without conversion for two structural reasons. First, the phosphate group makes psilocybin too hydrophilic and negatively charged to cross the blood-brain barrier by passive diffusion. Second, the phosphate group prevents psilocybin from fitting the 5-HT2A receptor binding site correctly. Removing the phosphate group creates psilocin, which is uncharged enough to cross membranes and structurally compatible with receptor binding. Mushrooms store psilocybin (not psilocin) because the phosphate form is more chemically stable — the body's alkaline phosphatase provides the activation step on demand.

Sources & References

1. 1RTHM-00867·Dinis-Oliveira, Ricardo Jorge (2017). “Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance..” Drug metabolism reviews.Study breakdown →PubMed →↩
2. 2RTHM-00461·Brown, Randall T et al. (2017). “Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults..” Clinical pharmacokinetics.Study breakdown →PubMed →↩
3. 3RTHM-00509·Geiger, Haden A et al. (2018). “DARK Classics in Chemical Neuroscience: Psilocybin..” ACS chemical neuroscience.Study breakdown →PubMed →↩
4. 4RTHM-00759·Glatfelter, Grant C et al. (2022). “Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice..” ACS pharmacology & translational science.Study breakdown →PubMed →↩